ISSN: 2230-9926

Available online at http://www.journalijdr.com

IJDR

International Journal of Development Research
Vol. 10, Issue, 12, pp. 42526-42531, December, 2020
https://doi.org/10.37118/ijdr.20533.12.2020

RESEARCH ARTICLE OPEN ACCESS

THE LANDSCAPE OF NANOTECHNOLOGY STRATEGIES AGAINST COVID-19: PRODUCTS AND DIAGNOSTICS, VACCINES AND TREATMENTS

Thyago José Arruda Pacheco[1*], Franciéle de Matos da Silva[2], Danielle Galdino de Souza[3], Victor Carlos Mello da Silva[4] and Raquel Santos Faria[5]

[1]Master degree in Nanoscience and Nanobiotechnology, Post-Graduation Program in Animal Biology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil; [2]Master degree in Biomedical Engineering Post-Graduation Program in Molecular Biology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil; [3]Master degree in Nanoscience and Nanobiotechnology, Post-Graduation Program in Nanoscience and Nanobiotechnology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil; [4]Post-Graduation Program in Animal Biology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil; [5]Ph.D in Animal Biology. Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil

ARTICLE INFO

Article History:
Received 20th September, 2020
Received in revised form
09th October, 2020
Accepted 14th November, 2020
Published online 30th December, 2020

Key Words:
Coronavirus,
COVID-19,
Severe Acute Respiratory Syndrome,
Nanotechnology, Nanomedicine.

****Corresponding author:***
Thyago José Arruda Pacheco

ABSTRACT

The pandemic state, declared by the World Health Organization, on March 11, 2020, has tested society's adaptability and response. A race against time to seek strategies to fight the disease of the new coronavirus contributes to the union of scientists from all over the world, including using nanotechnology Thus, the objective of the study was described the landscape of nanotechnology strategies against COVID-19,highlighting mainly the products and diagnostics, vaccines and treatments that are or can be used. A literature review was carried out in studies published from February to November2020 in PubMed, Scielo, and Google Scholar databases. According to the indexes of the various databases, search terms were used: "new coronavirus 2019", "COVID-19", "severe acute respiratory syndrome" Nanotechnology against COVID-19", "COVID-19 Vaccines" without any language restrictions. The use of nano-based materials has indicated a great potential against dissemination of COVID-19, with the production of products, diagnostics, vaccines and treatments. Our results demonstrate that nanotechnology offers processes, materials and tools that contribute to increase the sensitivity, agility and reliability of the diagnostic, in addition to providing more effective options for prevention, diagnostic and therapies.

Citation: ***Thyago José Arruda Pacheco, Franciéle de Matos da Silva, Danielle Galdino de Souza, Victor Carlos Mello da Silva and Raquel Santos Faria.*** "The landscape of nanotechnology strategies against COVID-19: products and diagnostics, vaccines and treatments*", International Journal of Development Research*, 10, (12), 42526-42531.

INTRODUCTION

In December 2019, there were the first outbreaks in China due to the novel coronavirus (SARS-COV-2). With the growing number of cases in several countries, on March 11, 2020, the world health organization declared the 2019 coronavirus disease pandemic (COVID-19). Since then, scientists from different countries share the same goal: to develop treatments, vaccines, diagnostics, and products against COVID-19 (Ahmed *et al*., 2020; Pacheco *et al*., 2020). The different technological strategies against COVID-19 allowed scientific and technological development also in the field of nanotechnology, presenting a great need to better understand and explore this novel nano-virus (60-140 nm in diameter) (Sportelli *et al*., 2020; Tabish & Hamblin, 2020; Talebian *et al*., 2020). Nanotechnology provides the development of systems under a dimension of fewer than 100 nanometers, with potential for both diagnostic, treatment, and prevention of diseases, through nanoparticles that have unique properties, presenting better solubility, biocompatibility, conductivity, reduced toxicity, and multifunctionality (Campos *et al*., 2020; Vazquez-Munoz & Lopez-Ribot, 2020). Nanotechnology applied to the medical field is known as nanomedicine, where nanomaterials are used for treatments, vaccines, diagnostics, or disease prevention products (Choi & Han, 2018).

Nanomedicine, for example, is capable of being used to improve immunogenicity with prophylactic approaches. Nanoparticles can work basically by increasing the activation of immunity so that it protects against disease (Yadav *et al*., 2018). Due to their size, 1-100 nm, nanotransporters such as liposomes, nanoemulsions, synthetic polymeric nanoparticles, proteasomes, nano-granules, inorganic nanomaterials, as well as biological polymeric nanoparticles (exosome, bacteriophage) have been widely tested and used in the prevention of infectious and non-infectious diseases, as they can be captured by cells by endocytosis, and thus release biologically active compounds (Zaman *et al*., 2013; Zhao *et al*., 2014). Another important feature of nanotechnology in the medical field is the ability to modify the surface and effectively co-deliver adjuvants, which makes nanoparticles a potential candidate for commercial vaccines. Also, nano adjuvants in vaccines protect the target antigen from degradation and increase absorption by immunological mediators of biological systems. This approach is malleable, having the ability to present the antigen in a repetitive manner leading to stable immunogenic properties (Vicente *et al*., 2010; Zhao *et al*., 2014). This type of nanomedicine-based approach has already been used against SARS-CoV-1 and MERS and now with SARS-COV-2 (Chan, 2020). Nanomedicine has been present in the modern world for decades, having its first product regulated by the Federal Drug Administration (FDA) in 1995 (Flühmann *et al*., 2019). There are many applications of nanomedicine for different uses. Here we highlight mainly the products and diagnostics, vaccines and treatments that are or can be used against COVID-19.

METHODS

A literature review was carried out in studies published from February to 12th November 2020 in PubMed, Scielo, and Google Scholar databases. According to the indexes of the various databases, search terms were used: "new coronavirus 2019", "COVID-19", "Nanotechnology against COVID-19", "COVID-19 Vaccines", "severe acute respiratory syndrome" without any language restrictions. Those who described a comparative overview of coronavirus, treatments, vaccines, diagnostics and products nano-based against COVID- 19 were eligible.

RESULTS

Products and diagnostics: During this fight against coronavirus 2019 (COVID-19), our main line of defense is our immune system; however, people who are immunocompromised or who have at least one underlying comorbidity are considered to be quite vulnerable and their only line of defense is disinfectants, facial masks, immune system stimulants and medications (Talebian *et al*., 2020) (**Fig. 1**). The nanotechnology field has grown a lot with these new technological advances, and several products based on nano or antiviral agents to block SARS-CoV-2 have been developed (Abu-Faraj, n.d.; Itani *et al*., 2020). Antimicrobial and antiviral formulations based on nanotechnology can prevent the spread of the SARS-CoV-2 virus, and the development of highly sensitive biosensors and detection platforms can contribute to the detection and diagnosis of COVID-19 (Talebian *et al*., 2020).



Figure 1. Nanotechnology approaches in the fight against COVID-19



Figure 2. Vaccines using nanotechnology. 1) Nanometric Virus carring "particles" of SARS-COV-2 (RNA or other subunits). 2) Nanoparticles carrying "particles" of SARS-COV-2. These particles inside of virus or nanoparticles are reponsible for stimulating factors (like viral proteins from SARS-COV-2) that causes imune response in several individues.



Figure 3. Nanoparticles inhibiting the effects of viral infections in three main ways. (I) blocking receptor binding and entering the cell, (II) inhibiting proliferation, and (III) viral inactivation

Viral disinfectants, produced using nano-effective antimicrobial and antiviral formulations, are suitable for disinfecting air and surfaces and are also effective in reinforcing personal protective equipment, such as face respirators. Metallic nanoparticles (silver, copper, titanium dioxide nanoparticles) have been proposed as alternatives due to their wide range of inherent antiviral activities, persistence, and ability to be effective at much lower doses (Sportelli *et al*., 2020). These nanomaterials have enormous potential as disinfectants against coronavirus, as they have intrinsic antiviral properties, such as the generation of reactive oxygen species (ROS) and photodynamic and photothermal capabilities. The adverse effects on human health and the environment of metallic nanomaterials can be avoided with the use of biodegradable (that is polymeric, lipid-based) nanomaterials (Talebian *et al*., 2020). Preliminary tests showed that the silver nanocluster coating/silica composite in disposable FFP3 face masks (3M TM) had viricidal effects against SARS-CoV-2 (Balagna *et al*., 2020). The Nano Tech Surface developed by Italy is a durable and self-sterilizing formula composed of titanium dioxide and silver ions to disinfect surfaces. Graphene sheets with antibodies have the potential to quickly detect targeted viral proteins and are also used for the development of environmental sensors and filters, due to the low cost of graphene materials.

Functionalized graphene has demonstrated a good capacity for viral capture that, combined with heat or light-mediated inactivation, can be used as a disinfectant (Palmieri & Papi, 2020). Reusable and recyclable graphene surgical masks with excellent superhydrophobic, photothermal performances, and excellent self-cleaning properties are commercially available (Zhong *et al*., 2020). Researchers in Egypt have developed a new device against SARS-CoV-2. This corresponds to a breathing filter mask design based on polylactic acid (PLA), a biodegradable and transparent polymer, cellulose acetate (CA), copper oxide nanoparticles (CuONPs), and graphene oxide (GO). The objective is to allow the polymeric network to prevent the entry of viral particles into the nasal cavity, while CuONPs and GO further inhibit the potential for viral transmission by inactivating the particles trapped in the membrane itself (Ahmed *et al*., 2020). Viral detection may be possible through the development of highly sensitive and accurate nanosensors that allow early diagnosis of COVID-19. Nanomaterials functionalized with nucleic acids or antibodies represent the main lines of detection based on nano, through colorimetric or antigen-binding assays, as well as light and photothermal platforms (Li *et al*., 2020). Researchers at the Korea Institute of Basic Sciences developed a field-effect transistor (FET) -based biosensor device to detect SARS-CoV-2 in clinical samples. The sensor was produced by coating FET graphene sheets with a specific antibody against the SARS-CoV-2 spike protein. Sensor performance was determined using antigen proteins, cultured viruses, and nasopharyngeal smear specimens from COVID-19 patients. This device has an extraordinary ability to distinguish the SARS-CoV-2 antigen protein from those of the MERS-CoV (Seo *et al*., 2020).

Vaccines: Data from November 12nd show that there are 19 vaccines, from 212, against COVID-19, being developed and that describe in their production method nanomedicine, such as lipid nanoparticles, liposomes, or viral particles (DRAFT landscape of COVID-19) (Seo *et al*., 2020). Four of them are already under clinical evaluation, three in phase 3 (Moderna/NIAID, Novavax and BioNTech/Fosun Pharma/Pfizer) and the one from Imperial College London in phase 1, the latter has not yet released its results so far (Table 1). All of these in the clinical phase use lipid nanoparticles encapsulating RNA encoding structures of the new coronavirus (*Draft Landscape of COVID-19 Candidate Vaccines*, n.d.) (Fig. 2). The potential vaccine in phase 3, RNA-1273, manufactured by Moderna TX Inc, is an mRNA-based vaccine encapsulated by lipid nanoparticles, which is capable of encoding the Spike (S) protein of the SARS-CoV-2 virus in the host cell. Since this RNA is encapsulated by lipid nanoparticles, the vaccine can be injected intramuscularly into patients. So, when injected, it takes the mRNA to host immune cells encoding the spike protein, so these cells make copies of the protein as if the cells have been infected by the coronavirus and then other immune cells can interact with these spike proteins and trigger the cascade effect of the immune system, leaving the individual protected against possible infection by the coronavirus. This technology took just 42 days to develop and induced anti-SARS-CoV-2 immune responses in all participants, with no limiting safety concerns identified in the trial (Jackson *et al*., 2020).

The other potential vaccine with phase 3 nanotechnology is BNT162b1, manufactured by BioNTech / Fosun Pharma / Pfizer. This is a nucleoside-modified mRNA vaccine, also formulated with lipid nanoparticles that encode the trimerized receptor (RBD) binding domain of the SARS-CoV-2 virus spike glycoprotein. The first results of BNT162b1 were published by Nature. Different doses were administered, with an acceptable tolerability and safety profile. The researchers are very optimistic for a rapid production of a vaccine against SARS-CoV-2 to prevent COVID- 19 (Mulligan *et al*., 2020). Finally, the third potential vaccine against COVID-19 in phase 3 using nanotechnology is produced by Novavax (NVX-CoV2373). This vaccine utilizes immunogenic virus-like nanoparticles based on recombinant expression of the S-protein. The results from phase 1-2 trial were detailed in the *New England Journal of Medicine*. The NVX-CoV2373 showed good results. being safe and triggered immune responses that exceeded levels in Covid-19 convalescent serum (Keech *et al*., 2020).

Treatments: Several nanobiotechnological platforms were able to combat human viruses, and preclinical studies, such as herpes, hepatitis B, HIV, in addition to some respiratory viruses (Jackman *et al*., 2016; Patel *et al*., 2017). These platforms can be used to develop therapies and diagnoses against SARS-CoV-2 or other future pandemics (Amanat & Krammer, 2020; Chan, 2020; Weiss *et al*., 2020). When analyzing the panorama of the therapeutic development of COVID-19 with other diseases, we can see that, in both cases, the most important thing is to align the correct drug with the most promising nanocarrier (Chauhan *et al*., 2020). Thus, we can infer that the challenges for the development of therapies against COVID-19, as well as for other viral diseases or even cancer, for example, are very similar. However, in general aspects, the encounter of the virus with the susceptible host is what makes viral infection possible. We can divide four especially important points of the relationship between viruses and host cells for the maintenance of the infectious process. First - the adsorption and penetration of the viral agent in the host; second - transcription, translation (synthesis) and maturation of the viable progeny; third - the release of the host's progeny; and fourth - the resistance of the viral agent to the adversities of the environment (Kostarelos, 2020).

Table 1. Description of vaccines based on nanoparticles against COVID-19 (On November 2020)

Nome	Organizações envolvidas	Método da vacina	Fase
Moderna/NIAID	National Institutes of Health (NIH) and Moderna (United States)	LNP (lipid nanoparticles) -encapsulated mRNA	Fase 1 NCT04283461 Fase 2 NCT04405076 Fase 3 NCT04470427
Novavax	Novavax, Inc. (United States)	Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	Fase ½ NCT04368988 Fase 2b NCT04533399 Fase 3 2020-004123-16 NCT04611802
Ad5-nCoV	CanSino Biological Inc./Beijing Institute of Biotechnology *(China)*	Adenovirus vector 5, containing SARS-CoV-2 S nanoparticles	Fase 1 ChiCTR2000030906 NCT04568811 Fase 2 ChiCTR2000031781 NCT04566770 Fase 3 NCT04526990 NCT04540419
BNT162 (a1, b1, b2, c2)	BioNTech/Fosun Pharma/Pfizer/ (United States / Germany)	LNP-encapsulated mRNA	Fase 1 NCT04368728 Fase ½ 2020-001038-36 ChiCTR2000034825 NCT04537949 Fase 3 NCT04368728
LNP-nCoVsaRNA	Imperial College London (England)	LNP encapsulated self-amplifying RNA (saRNA)	Fase 1 ISRCTN17072692
Vaccine candidate	Max-Planck-Institute of Colloids and Interfaces (Germany)	LNP-encapsulated mRNA encoding the receptor binding domain (RBD) of protein SARS-CoV-2	Pre-Clinical
Vaccine candidate	Bio/Sanofi Pasteur (France)	LNP-encapsulated mRNA	Pre-Clinical
Vaccine candidate	*CanSino Biologics / Precision NanoSystems (China / Canada)*	LNP-encapsulated mRNA	Pre-Clinical
Vaccine candidate	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma *(China)*	LNP-encapsulated mRNA encoding RBD of protein S SARS-CoV-2	Pre-Clinical
Vaccine candidate	Fudan University/ Shanghai JiaoTong University/RNACure Biopharma *(China)*	LNP-encapsulated mRNA cocktail encoding VLP	Pre-Clinical
Vaccine candidate	University of Tokyo/ Daiichi-Sankyo *(Japan)*	LNP-encapsulated mRNA	Pre-Clinical
Vaccine candidate	BIOCAD (Russia)	Liposome-encapsulated mRNA	Pre-Clinical
Vaccine candidate	Chula Vaccine Research Center/University of Pennsylvania (United States)	LNP-encapsulated mRNA	Pre-Clinical
Vaccine candidate	National institute of Chemistry (Slovenia)	Plasmid DNA, nanostructured RBD	Pre-Clinical
Vaccine candidate	Ohio State University / Kazakh National Agrarian University (United States/ Kazakh)	RBD protein delivered in mannoseconjugated chitosan nanoparticle	Pre-Clinical
Vaccine candidate	Saint-Petersburg scientific research institute of vaccines and serums (Russia)	Recombinant protein, nanoparticles (based on S-protein and other epitopes)	Pre-Clinical
Vaccine candidate	LakePharma, Inc (United States)	Nanoparticle vaccine	Pre-Clinical
Vaccine candidate	IMV Inc (Canada)	Peptide antigens formulated in LNP	Pre-Clinical
Vaccine candidate	Globe Biotech Ltd (Bangladesh)	D614G variant LNP-encapsulated mRNA	Pre-Clinical

According to that, we can also observe that therapeutic drugs based on NP can inhibit the effects of viral infections in three main ways (I) blocking receptor binding and entering the cell, (II) inhibiting viral infection, and (III) viral inactivation. (I) Blocking the binding to the receptor and entering the cell, as shown in the work by Huang *et al*, where the AuNRs nanoparticle blocked the entry of the MERS virus AgNPs showed efficient antiviral activity against RSV (herpes simplex virus) infection by directly inactivating the virus before entering host cells(Huang *et al*., 2019). Silica nanoparticles (SiNPs) can act as efficient eliminators of the human immunodeficiency virus (HIV) and the respiratory syncytial virus (RSV) (Souza *et al*., 2016). (II) The inhibition of viral infection, as shown in the study by Lin and coauthors (2017), Se @ ZNV (selenium nanoparticles with the antiviral zanamivir) revealed good biological activity to contain the proliferation of the influenza virus H1N1 (Osminkina *et al*., 2014). According to Souza *et al*. (2016) SiO NPs were able to inhibit HIV infection, showing that the use of these functionalized silica particles presented a promising approach for the control of HIV infection and viral control (Souza *et al*., 2016). (III) Viral inactivation, as presented in the study by Ghaffari *et al*., (2019) the PEGylated ZnO-NPs nanoparticles had an antiviral activity with inhibitory properties against the H1N1 influenza virus. Kong *et al*. (2019) observed that nanodisks inhibited the infection of the influenza virus H1N1, even suggesting nanodisks as therapeutic agents against enveloped viruses (Fig. 3) Despite the treatment options currently proposed, the number of serious cases and deaths of patients infected with SARS-CoV-2 is still high. Much of the side effects of antivirals are caused by their accumulation in off-target organs. Nanoparticles can optimize drug delivery to target infection sites and with controlled release properties (Chhikara *et al*., 2020). Therefore, we must also focus on alternative approaches, such as nanotechnology, to achieve an effective treatment for this disease and to minimize the side effects of the compounds.

Conclusion

There are several options for products, treatments, and vaccines nano-based against COVID-19. The great hope is placed on vaccines and three of them, in phase 3, use nanotechnology. Nanomedicine has already demonstrated its ability to protect, diagnose, and treat other viral diseases or infections; therefore, it may also have a great capacity to fight COVID-19. One of the biggest challenges is ensuring the safe use of these nanomaterials for the entire world population.

Acknowledgements

The authors gratefully acknowledge financial support from: the Brazilian National Council for Technological and

Scientific Development (CNPq), Coordinating Agency for Advanced Training of Graduate Personnel (CAPES), Foundation for Research Support of the Federal District (FAPDF) an the Dean of Research and Post-Graduation of the University of Brasília (DPP-UnB).

REFERENCES

Abu-Faraj, Z. O. (n.d.). Covid-19 Pandemic: Lessons to Learn from China. *LinkedIn Pulse*, *9*.

Ahmed, M. K., Afifi, M., & Uskoković, V. (2020). Protecting healthcare workers during COVID-19 pandemic with nanotechnology: A protocol for a new device from Egypt. *Journal of Infection and Public Health*, *13*(9), 1243–1246. https://doi.org/10.1016/j.jiph.2020.07.015

Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines : Status Report. *Immunity*, *52*(583–589).

Balagna, C., Perero, S., Percivalle, E., Vecchio, E., & Ferraris, M. (2020). Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/ silica composite sputtered coating. *Open Ceramics*, *1*(2666–5395), 3.

Campos, E. V. R., Pereira, A. E. S., De Oliveira, J. L., Carvalho, L. B., Guilger-Casagrande, M., De Lima, R., & Fraceto, L. F. (2020). How can nanotechnology help to combat COVID-19? Opportunities and urgent need. *Journal of Nanobiotechnology*, *18*(1), 1–23. https://doi.org/10.1186/s12951-020-00685-4

Chan, W. C. W. (2020). Nano Research for COVID-19 [Editorial]. *ACS Nano*, *14*, 3719–3720. https://doi.org/10.1021/acsnano.0c02540

Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., & Ghosh, D. (2020). Nanotechnology for COVID-19: Therapeutics and Vaccine Research. *ACS Nano*, *14*(7), 7760–7782. https://doi.org/10.1021/acsnano.0c04006

Chhikara, B. S., Rathi, B., Singh, J., & Poonam, F. N. U. (2020). Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics: A review on Corona Virus Disease COVID-19, epidemiology, prevention, and anticipated therapeutic advances. *Journal of Materials NanoScience*, *7*(1), 63–72.

Choi, Y. H., & Han, H.-K. (2018). Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. *Journal of Pharmaceutical Investigation*, *48*(1), 43–60.

de Souza, E. S. J. M., Hanchuk, T. D., Santos, M. I., Kobarg, J., Bajgelman, M. C., & Cardoso, M. B. (2016). Viral Inhibition Mechanism Mediated by Surface-Modified Silica Nanoparticles. *ACS Applied Materials & Interfaces*, *8*(26), 16564.

Draft landscape of COVID-19 candidate vaccines. (n.d.). Retrieved September 18, 2020, from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Flühmann, B., Ntai, I., Borchard, G., Simoens, S., & Mühlebach, S. 2019. Nanomedicines: The magic bullets reaching their target? *European Journal of Pharmaceutical Sciences*, *128*(September 2018), 73–80. https://doi.org/10.1016/j.ejps.2018.11.019

Ghaffari, H., Tavakoli, A., Moradi, A., Tabarraei, A., Bokharaei-Salim, F., Zahmatkeshan, M., Farahmand, M., Javanmard, D., Kiani, S. J., Esghaei, M., Pirhajati-Mahabadi, V., Ataei-Pirkooh, A., & Monavari, S. H. 2019. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: Another emerging application of nanomedicine. *Journal of Biomedical Science*, *26*(1), 1–10. https://doi.org/10.1186/s12929-019-0563-4

Huang, X., Li, M., Xu, Y., Zhang, J., Meng, X., An, X., Sun, L., Guo, L., Shan, X., Ge, J., Chen, J., Luo, Y., Wu, H., Zhang, Y., Jiang, Q., & Ning, X. 2019. Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus [Research-article]. *ACS Applied Materials and Interfaces*, *11*(22), 19799–19807. https://doi.org/10.1021/acsami.9b04240

Itani, R., Tobaiqy, M., & Faraj, A. Al. (2020). Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients. *Theranostics*, *10*(13), 5932–5942. https://doi.org/10.7150/thno.46691

Jackman, J. A., Lee, J., & Cho, N.-J. (2016). Nanomedicine for infectious disease applications: innovation towards broad-spectrum treatment of viral infections. *Small*, *12*(9), 1133–1139.

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., Beigel, J. H. (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine*. https://doi.org/10. 1056/nejmoa 2022483

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., & others. (2020). Phase 1--2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *New England Journal of Medicine*.

Kong, B., Moon, S., Kim, Y., Heo, P., Jung, Y., Yu, S. H., Chung, J., Ban, C., Kim, Y. H., Kim, P., Hwang, B. J., Chung, W. J., Shin, Y. K., Seong, B. L., & Kweon, D. H. (2019). Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-018-08138-1

Kostarelos, K. (2020). Nanoscale nights of COVID-19. *Nature Nanotechnology*, *15*, 343–344. https://doi.org/10.1038/s41565-020-0687-4

Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., Sun, R., Wang, Y., Hu, B., Chen, W., & others. (2020). Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *Journal of Medical Virology*.

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Walsh, E. E., Jansen, K. U. (2020). Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. https://doi.org/10.1038/s41586-020-2639-4

Osminkina, L. A., Timoshenko, V. Y., Shilovsky, I. P., Kornilaeva, G. V., Shevchenko, S. N., Gongalsky, M. B., Tamarov, K. P., Abramchuk, S. S., Nikiforov, V. N., Khaitov, M. R., & Karamov, E. V. (2014). Porous silicon nanoparticles as scavengers of hazardous viruses. *Journal of Nanoparticle Research*, *16*(6). https://doi.org/ 10.1007/s11051-014-2430-2

Pacheco, T. J. A., da Silva, F. de M., DE SOUZA, D. G., da Silva, V. C. M., & Faria, R. S. (2020). Coronavirus disease 2019 (COVID-19): Updated evidence of comparative overview, diagnosis and treatments. *Revista Cereus*, *12*(3), 228–243.

Palmieri, V., & Papi, M. 2020. Can graphene take part in the fight against COVID-19? *Nano Today*, *33*(1748–0132), 1–4. https://doi.org/10.1016/j.nantod.2020.100883

Patel, S., Singh, D., Srivastava, S., Singh, M., Shah, K., Chauahn, D. N., & Chauhan, N. S. 2017. Nanoparticles as a platform for antimicrobial drug delivery. *Adv Pharma Pharmacy*, *5*, 31–43.

Seo, G., Lee, G., Kim, M. J., Baek, S. H., Choi, M., Ku, K. B., Lee, C. S., Jun, S., Park, D., Kim, H. G., Kim, S. J., Lee, J. O., Kim, B. T., Park, E. C., & Kim, S. Il. 2020. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano*, *14*(4), 5135–5142. https://doi.org/10.1021/acsnano.0c02823

Sportelli, M. C., Izzi, M., Kukushkina, E. A., Hossain, S. I., Picca, R. A., Ditaranto, N., & Cioffi, N. 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? *Nanomaterials*, *10*(4), 802.

Tabish, T. A., & Hamblin, M. R. 2020. Multivalent nanomedicines to treat COVID-19: A slow train coming. *Nano Today*, *35*(1748–0132), 4. https://doi.org/10.1016/ j.nantod.2020.100962

Talebian, S., Wallace, G. G., Schroeder, A., Stellacci, F., & Conde, J. 2020. Nanotechnology-based disinfectants and sensors for SARS-CoV-2. *Nature Nanotechnology*, *15*(8), 618–621. https://doi.org/10.1038/s41565-020-0751-0

Vazquez-Munoz, R., & Lopez-Ribot, J. L. 2020. Nanotechnology as an Alternative to Reduce the Spread of COVID-19. *Challenges*,*11*(2),15.https://doi.org/ 10.3390/challe11020015

Vicente, S., Prego, C., Csaba, N., & Alonso, M. J. 2010. From single-dose vaccine delivery systems to nanovaccines. *Journal of Drug Delivery Science and Technology*, *20*(4), 267–276. https://doi.org/10.1016/S1773-2247(10)50044-3

Weiss, C., Carriere, M., Fusco, L., Fusco, L., Capua, I., Regla-Nava, J. A., Pasquali, M., Pasquali, M., Pasquali, M., Scott, J. A., Vitale, F., Vitale, F., Unal, M. A., Mattevi, C., Bedognetti, D., Merkoçi, A., Merkoçi, A., Tasciotti, E., Tasciotti, E., Delogu, L. G. 2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. *ACS Nano*, *14*(6), 6383–6406. https://doi.org/10.1021/ acsnano. 0c03697

Yadav, H. K. S., Dibi, M., Mohammad, A., & Srouji, A. E. 2018. Nanovaccines formulation and applications-a review. *Journal of Drug Delivery Science and Technology*, *44*(September 2017), 380–387. https://doi.org/10.1016 /j.jddst.2018.01.015

Zaman, M., Good, M. F., & Toth, I. 2013. Nanovaccines and their mode of action. *Methods*, *60*(3), 226–231. https://doi.org/10.1016/j.ymeth.2013.04.014

Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. 2014. Nanoparticle vaccines. *Vaccine*, *32*, 327–337.

Zhong, H., Zhu, Z., Lin, J., Cheung, C. F., Lu, V. L., Yan, F., Chan, C. Y., & Li, G. 2020. Reusable and Recyclable Graphene Masks with Outstanding Superhydrophobic and Photothermal Performances. *ACS Nano*, *14*(5), 6213–6221. https://doi.org/10.1021/acsnano.0c02250

****